Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels

Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is restricted due to the risk of potentially life-threatening side effects, such as agranulocytosis. Although this restriction ensures safety against haematological risks, some patients with refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Takanobu, Keisuke, Hashimoto, Naoki, Ishikawa, Shuhei, Kusumi, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562318/
https://www.ncbi.nlm.nih.gov/pubmed/36229076
http://dx.doi.org/10.1136/bcr-2021-247734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562318/
https://www.ncbi.nlm.nih.gov/pubmed/36229076
http://dx.doi.org/10.1136/bcr-2021-247734

Ejemplares similares